Corrigendum to “Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic” [Adv. Drug Delivery Rev. 179 (2021) 114000]

Jain, Samagra; Venkataraman, Abhijeet; Wechsler, Marissa E.; Peppas, Nicholas A.

doi:10.1016/j.addr.2022.114501

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Frequent subcutaneous injections are always associated with pain, tenderness, local tissue necrosis, microbial contamination, and nerve damage [10][11][12]. In recent decades, a number of alternative insulin delivery methods involving micro-or nanotechnologies have been developed to overcome the limitations and drawbacks of conventional delivery [13][14][15][16][17] Particularly methods that can achieve non-invasive administration [13,18]. Long-term release [19] or closed-loop based smart delivery [17,20] are highly desirable.…”

Section: Introductionmentioning

confidence: 99%

New Approaches to Improve the Intranasal Absorption of Insulin

Mishra,

Suman,

Singh

2024

jaz

View full text Add to dashboard Cite

Insulin is essential for type 1 and advanced type 2 diabetics to maintain blood glucose levels and prolong lives. Due to its large molecular weight and short half-life, it has been usually administered subcutaneously accompanied with side effects such as the possibility of hypoglycemia episodes, weight gain, pain, local tissue necrosis, infection, nerve damage and inadequate post meal glucose control. In order to overcome these limitations, alternative delivery routes of insulin are expected to provide better safety and compliance for the patient. Non-invasive insulin delivery system represents one of the most challenging goals for pharmaceutical industry. Nasal insulin delivery has been extensively studied as an alternative to subcutaneous injection for the treatment of diabetes. The pharmacokinetic profile of nasal insulin is similar to that obtained by intravenous injection. Nasal drug administration has been used as an alternative route for the local or systemic availability of drugs restricted to intravenous administration. This is due to the large surface area, porous endothelial membrane, high total blood flow, the avoidance of first-pass metabolism and ready accessibility. The nasal administration of drugs, including numerous compound, peptide and protein drugs, for systemic medication has been widely investigated in recent years. Drugs are cleared rapidly from the nasal cavity after intranasal administration, resulting in rapid systemic drug absorption. This review describes the main barriers preventing nasal insulin absorption and special attention is given to new approaches to improve the intranasal absorption of insulin, including the application of new safe absorption enhancers and the use of appropriate delivery systems. It seems that bioadhesive delivery systems or water-insoluble powders with absorption enhancers are the most promising methods for intranasal delivery of insulin.

show abstract

Section: Introductionmentioning

confidence: 99%

New Approaches to Improve the Intranasal Absorption of Insulin

Mishra,

Suman,

Singh

2024

jaz

View full text Add to dashboard Cite

show abstract

“…7 Exogenous insulin injection interventions are one of the most important means of treating diabetes, but the dose of subcutaneous insulin injections usually does not produce a close physiological match with blood glucose concentrations and can even cause serious side effects such as hypoglycemia and renal failure. 8 To improve the controllability of insulin delivery, a closed-loop insulin delivery system based on GOx has therefore stimulated the scientific community's interest. The main principle is that GOx catalyzes the oxidation of glucose in the bloodstream, which changes the microenvironmental state and triggers changes in the structure and conformation of the carrier, leading to the release of preloaded insulin.…”

Section: Introductionmentioning

confidence: 99%

Recent advances in glucose-oxidase-based nanocomposites for diabetes diagnosis and treatment

Yang

Cai

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

“…LNPs are currently the most performing RNA delivery systems, [18][19][20] as demonstrated by the recent success of the messenger ribonucleic acid (mRNA) LNP COVID-19 vaccines. [21] The LNPs used in this study are composed of an ionizable cationic lipid that, at low pH, can electrostatically complex with the anionic inosinic and cytidylic acid residues in the poly(I:C) backbone. LNPs protect nucleic acids from degradation in the extracellular medium and can be efficiently taken up by actively phagocytic cells in lymphoid tissues.…”

Section: Introductionmentioning

confidence: 99%

Lipid Nanoparticle Encapsulation Empowers Poly(I:C) to Activate Cytoplasmic RLRs and Thereby Increases Its Adjuvanticity

Lamoot,

Jangra,

Laghlali

et al. 2023

Small

View full text Add to dashboard Cite

Poly(I:C) is a synthetic analogue of dsRNA capable of activating both TLR3 and RLRs, such as MDA‐5 and RIG‐I, as pathogen recognition receptors. While poly(I:C) is known to provoke a robust type I IFN, type III IFN, and Th1 cytokine response, its therapeutic use as a vaccine adjuvant is limited due to its vulnerability to nucleases and poor uptake by immune cells. is encapsulated poly(I:C) into lipid nanoparticles (LNPs) containing an ionizable cationic lipid that can electrostatically interact with poly(I:C). LNP‐formulated poly(I:C) triggered both lysosomal TLR3 and cytoplasmic RLRs, in vitro and in vivo, whereas poly(I:C) in an unformulated soluble form only triggered endosomal‐localized TLR3. Administration of LNP‐formulated poly(I:C) in mouse models led to efficient translocation to lymphoid tissue and concurrent innate immune activation following intramuscular (IM) administration, resulting in a significant increase in innate immune activation compared to unformulated soluble poly(I:C). When used as an adjuvant for recombinant full‐length SARS‐CoV‐2 spike protein, LNP‐formulated poly(I:C) elicited potent anti‐spike antibody titers, surpassing those of unformulated soluble poly(I:C) by orders of magnitude and offered complete protection against a SARS‐CoV‐2 viral challenge in vivo, and serum from these mice are capable of significantly reducing viral infection in vitro.

show abstract

Corrigendum to “Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic” [Adv. Drug Delivery Rev. 179 (2021) 114000]

Cited by 4 publications

References 0 publications

New Approaches to Improve the Intranasal Absorption of Insulin

New Approaches to Improve the Intranasal Absorption of Insulin

Recent advances in glucose-oxidase-based nanocomposites for diabetes diagnosis and treatment

Lipid Nanoparticle Encapsulation Empowers Poly(I:C) to Activate Cytoplasmic RLRs and Thereby Increases Its Adjuvanticity

Contact Info

Product

Resources

About